PATENT ABSTRACTS

5286851

M O N O C L O N A L A N T I B O D I E S T O A N T H R A C Y C L I N E S

Andrea Balsari, Maria I Colnagh, Marl Ghione, Milan, Italy assigned to Istituto Nazionale per 1o Studio e la Cura Dei Tumori

Monoclonal antibodies able to selectively bind to doxorubicin and its analogues and derivatives are disclosed.

5286852

A N T I B O D I E S S P E C I F I C T O W A R D S H I V - 1 G P 48

Kurt Osther assigned to Verigen Inc

Monoclonal and polyclonal antibodies specific towards, gp 48, having a molecular weight ranging from 46 kDa to 53 kDa. The gp 48 anti- bodies bind to the CD4 receptors on T4 lympho- cytes, inhibiting if not neutralizing the HIV-I virus from reacting therewith. Anti-gp 48 can be used for diagnosing AIDS and related diseases.

5288487

H U M A N M O N O C Y T E - M A C R O P H A G E - C S F

P R E P A R A T I O N S

Takuji Kawashima, Nobuya Yanai, Muneo Yamada, Hajime Yokota, Kunio Ujiie, Katsuo Yoshida, Shinya Suzu, Fumimaro Takaku, Kazuo Motoyoshi, Nobuhiro Yamada, Kawasaki, Japan assigned to Morinaga Milk Industry Co Ltd

Human M-CSF preparations and recombinant human M-CSF preparations against myelodysplastic syndrome, malignant tumor and hyperlipemia and auxiliary therapeutic pre- parations to be dosed along with platinum- complex anticancer preparations.

5288614

M E T H O D F O R T H E D E T E C T I O N O F M A L I G N A N T D I S E A S E S

Hein Bodenmuller, Andreas Dessauer, Tutzing, Federal Republic Of Germany assigned to Boehringer Manoheim GmbH

607

In order to aid in the detection of malignant dis- eases the sample of a body fluid is incubated with at least two receptors R1 and R2 in which a signal change is produced by binding of at least the receptors R1 and R2 to the substance to be detected in the sample solution and in which one of the two receptors contains a monoclonal anti- body which binds to the amino acid sequence 311 to 335 of cytokeratin 19 and the other receptor contains a monoclonal antibody which binds to the amino acid sequence 346 to 359 of cyto- keratin 19 and the signal change in the sample caused by the binding is determined.

5288615

M E T H O D S F O R P R E P A R I N G P R O T E I N S O F A L T E R E D

S T R U C T U R E

Annette T Lee, Anthony Cerami assigned to The Rockefeller University

The present invention relates to methods for in- ducing cellular mutation by promoting the reac- tion of nonenzymatic glycosylation of genetic material, such as DNA and RNA, by incubation of the genetic material with certain protein struc- ture modifying agents. Suitable such agents are reducing sugars, such as glucose, glucose-6- phosphate and a reactive intermediate com- prising a complex between glucose 6-phosphate and lysine. The methods include the in vitro reac- tion of the agent with genetic material, such as a particular gene-bearing plasmid, under condi- tions promoting mutation followed by the in- troduction of the plasmid bearing the reacted gene into a host cell, and allowing the reacted gene to be mutated and expressed, after which the mutant protein of interest may be isolated. In a variation on the last-mentioned method, a first genetic material may be incubated withthe agent and reacted, and this reacted genetic material may then be introduced into a distinct cellular strain and appropriately incubated whereupon the first reacted genetic material will cause the mutation of the genetic material in the distinct cellular strain. The invention also includes an in vivo embodiment wherein the particular genetic material of interest may be isolated and in- troduced into a host cell which contains high intracellular concentrations of the protein strut-